Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 8/20 | 0.50 |
| ▸ | ADH1C | P00326 | 5/20 | 0.50 |
| ▸ | PHGDH | O43175 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADH4 | P08319 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15595 | 1.00 | — | — | |
| SCHEMBL28469806 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL612962 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL3080635 | 1.00 | — | — | |
| SCHEMBL13356252 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL283931 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL1674941 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL1679002 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL20733112 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL28251831 | 1.00 | ADH1A (0.50) | ADH1AADH1CPHGDHFAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220205992-A1 | MATERIALS AND KITS RELATING TO ASSOCIATION OF REPORTER SPECIES AND TARGETING ENTITIES WITH BEADS | Quanterix Corporation (US) | 2022-06-30 | — | — | US | disclosed |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10435375-B2 | CXCR4 chemokine receptor modulators | NORTHWESTERN UNIVERSITY (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2019-06-27 | — | — | US | disclosed |
| US-20180155295-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | NORTHWESTERN UNIVERSITY | 2018-06-07 | — | — | US | disclosed |
| EP-2421874-B1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2015-09-30 | — | — | EP | disclosed |
| US-8979996-B2 | Composition containing quaternary amino-functional organosilicon compunds and production and use thereof | EVONIK DEGUSSA GMBH (DE) | 2015-03-17 | — | — | US | disclosed |
| US-20140208981-A1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2014-07-31 | — | — | US | disclosed |
| US-8728225-B2 | Composition containing quaternary amino-functional organosilicon compounds and production and use thereof | EVONIK DEGUSSA GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-20120037040-A1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2012-02-16 | — | — | US | disclosed |
| EP-0054748-B1 | PROCESS FOR THE PREPARATION OF AQUEOUS SOLUTIONS OF CATIONIC ORGANOSILICIUM COMPOUNDS | Degussa Aktiengesellschaft (DE) | 1984-09-26 | — | — | EP | disclosed |
| US-4390712-A | Aqueous solution of cationic organosilicon compounds and process for the production of the solutions | DEGUSSA AG (DE) | 1983-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435375-B2 | CXCR4 chemokine receptor modulators | CXCR4, ACKR3, CXCR3 | ADH1A 2418/4885ADH1C 3168/4885PHGDH 3868/4885 |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | ADH1A 2703/4885ADH1C 3898/4885PHGDH 1684/4885 |
| US-20180155295-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | CXCR4, ACKR3, CXCR3 | ADH1A 2418/4885ADH1C 3168/4885PHGDH 3868/4885 |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | ADH1A 2703/4885ADH1C 3898/4885PHGDH 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.